Charles River Laboratories Long Term Debt 2010-2024 | CRL

Charles River Laboratories long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
  • Charles River Laboratories long term debt for the quarter ending June 30, 2024 was $2.409B, a 10.05% decline year-over-year.
  • Charles River Laboratories long term debt for 2023 was $2.647B, a 2.23% decline from 2022.
  • Charles River Laboratories long term debt for 2022 was $2.708B, a 1.65% increase from 2021.
  • Charles River Laboratories long term debt for 2021 was $2.664B, a 38.04% increase from 2020.
Charles River Laboratories Annual Long Term Debt
(Millions of US $)
2023 $2,647
2022 $2,708
2021 $2,664
2020 $1,930
2019 $1,850
2018 $1,637
2017 $1,114
2016 $1,208
2015 $846
2014 $741
2013 $642
2012 $527
2011 $703
2010 $670
2009 $457
Charles River Laboratories Quarterly Long Term Debt
(Millions of US $)
2024-06-30 $2,409
2024-03-31 $2,660
2023-12-31 $2,647
2023-09-30 $2,514
2023-06-30 $2,678
2023-03-31 $2,744
2022-12-31 $2,708
2022-09-30 $2,937
2022-06-30 $2,997
2022-03-31 $2,676
2021-12-31 $2,664
2021-09-30 $2,893
2021-06-30 $2,727
2021-03-31 $2,202
2020-12-31 $1,930
2020-09-30 $1,968
2020-06-30 $2,207
2020-03-31 $2,327
2019-12-31 $1,850
2019-09-30 $1,883
2019-06-30 $2,040
2019-03-31 $1,541
2018-12-31 $1,637
2018-09-30 $1,653
2018-06-30 $1,796
2018-03-31 $1,130
2017-12-31 $1,114
2017-09-30 $1,156
2017-06-30 $1,116
2017-03-31 $1,170
2016-12-31 $1,208
2016-09-30 $1,233
2016-06-30 $1,331
2016-03-31 $840
2015-12-31 $846
2015-09-30 $836
2015-06-30 $755
2015-03-31 $755
2014-12-31 $741
2014-09-30 $755
2014-06-30 $782
2014-03-31 $614
2013-12-31 $642
2013-09-30 $624
2013-06-30 $620
2013-03-31 $518
2012-12-31 $527
2012-09-30 $543
2012-06-30 $551
2012-03-31 $675
2011-12-31 $703
2011-09-30 $720
2011-06-30 $731
2011-03-31 $761
2010-12-31 $670
2010-09-30 $701
2010-06-30 $409
2010-03-31 $438
2009-12-31 $457
2009-09-30 $464
2009-06-30 $486
2009-03-31 $474
Sector Industry Market Cap Revenue
Medical Medical Services $9.742B $4.129B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $96.890B 12.02
Cencora (COR) United States $46.107B 17.62
DiDi Global (DIDIY) China $23.233B 0.00
ICON (ICLR) Ireland $18.679B 16.64
Revvity (RVTY) United States $15.535B 26.63
Avantor (AVTR) United States $15.498B 23.24
Natera (NTRA) United States $15.385B 0.00
Viatris (VTRS) United States $13.858B 4.22
BioMerieux (BMXMF) France $13.601B 0.00
Solventum (SOLV) United States $12.636B 0.00
CochLear (CHEOY) Australia $12.565B 0.00
Medpace Holdings (MEDP) United States $10.202B 28.74
Sonic Healthcare (SKHHY) Australia $8.273B 0.00
HealthEquity (HQY) United States $7.792B 42.29
Doximity (DOCS) United States $7.787B 49.34
Bausch + Lomb (BLCO) Canada $6.975B 32.47
Life Times (LTH) United States $4.762B 31.52
PACS (PACS) United States $4.502B 0.00
Sotera Health (SHC) United States $4.367B 23.36
Organon (OGN) United States $4.239B 4.28
Surgery Partners (SGRY) United States $3.778B 41.86
BrightSpring Health Services (BTSG) United States $3.070B 65.30
Ardent Health Partners (ARDT) United States $2.577B 0.00
Alignment Healthcare (ALHC) United States $2.546B 0.00
Concentras Parent (CON) United States $2.480B 0.00
Premier (PINC) United States $2.271B 11.34
GoodRx Holdings (GDRX) United States $2.254B 84.86
GeneDx Holdings (WGS) United States $2.057B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
Teladoc Health (TDOC) United States $1.575B 0.00
AMN Healthcare Services Inc (AMN) United States $1.507B 7.57
Progyny (PGNY) United States $1.425B 25.06
Establishment Labs Holdings (ESTA) $1.338B 0.00
Pediatrix Medical (MD) United States $1.319B 12.91
CareDx (CDNA) United States $1.228B 0.00
Agilon Health (AGL) United States $1.123B 0.00
Embecta (EMBC) United States $0.864B 5.76
InnovAge Holding (INNV) United States $0.822B 0.00
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
SBC Medicals (SBC) United States $0.722B 0.00
Auna S.A (AUNA) Luxembourg $0.488B 0.00
Sonida Senior Living (SNDA) United States $0.483B 0.00
Enhabit (EHAB) United States $0.382B 33.04
DocGo (DCGO) United States $0.355B 13.35
COMPASS Pathways (CMPS) United Kingdom $0.309B 0.00
Sera Prognostics (SERA) United States $0.255B 0.00
ModivCare (MODV) United States $0.232B 7.37
Beauty Health (SKIN) United States $0.211B 0.00
Biodesix (BDSX) United States $0.195B 0.00
LifeMD (LFMD) United States $0.192B 0.00
Ascend Wellness Holdings (AAWH) United States $0.178B 0.00
MultiPlan (MPLN) United States $0.136B 0.00
Nutex Health (NUTX) United States $0.127B 0.00
So-Young (SY) China $0.092B 22.35
Harvard Apparatus Regenerative Technology (HRGN) United States $0.059B 0.00
Singular Genomics Systems (OMIC) United States $0.057B 0.00
OncoCyte (OCX) United States $0.049B 0.00
NeueHealth (NEUE) United States $0.041B 1.63
Co-Diagnostics (CODX) United States $0.039B 0.00
IceCure Medical (ICCM) Israel $0.036B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.027B 0.00
Pheton Holdings (PTHL) China $0.027B 0.00
Oncology Institute (TOI) United States $0.021B 0.00
SeaStar Medical Holding (ICU) United States $0.012B 0.00
XWELL (XWEL) United States $0.009B 0.00
Intelligent Bio Solutions (INBS) United States $0.007B 0.00
BioNexus Gene Lab (BGLC) $0.007B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00